Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript

Operator: Hi, everyone. I'm Jill Hall, Head of U.S. Small and Mid-cap Strategy here at BofA Global Research. So, I just wanted to welcome everyone to our day 1 of our virtual SMidCap event, excited to hear from corporates across the small and mid-cap space across sectors, great breadth of coverage here by our analysts. They cover about 1,000 small and mid-caps in the U.S. So, I'm happy to bring nearly 20 companies today and feel free to reach out to me if I can help with the schedule or getting you signed up for any additional sessions, or if you're interested in broader small- and mid-cap research, or some of our compilation e-mails we send out on the fundamental side. So I'd like to pass it over to Alec for this session to introduce the company.

Alec Stranahan: BofA Securities, Research Division Perfect. Thanks, Jill. As Jill said, my name is Alec Stranahan. I'm senior analyst covering biotech here at BofA. I cover around 30 stocks ranging from $40 billion all the way down to $400 million in market cap. And one of the more interesting names, I would say, is Recursion, and it's my pleasure to be joined by Ben Taylor, who is Chief Financial Officer and President of Recursion U.K. And I would say speaks just about as well about the science and AI aspects of Recursion as he does about the finance side. So Ben, really happy to have you with us.

Ben Taylor: CFO & President of Recursion UK Thanks, Alec. I always appreciate the intro